Evidence map›Paper›PMID 23026838›Full record

ArticlePsychiatric services (Washington, D.C.)2012

The effect of race-ethnicity and geography on adoption of innovations in the treatment of schizophrenia.

Marcela Horvitz-Lennon, Margarita Alegría, Sharon-Lise T Normand

Abstract read
In one paragraph

Article in Psychiatric services (Washington, D.C.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Marcela Horvitz-LennonRAND Corporation, 4570 Fifth Ave., Suite 600, Pittsburgh, PA 15213, USA. mhorvitz@rand.org
Margarita Alegría
Sharon-Lise T Normand
Cambridge Health Alliance · US

Funding

UPR-CHA Research Center of Excellence: Making a Difference for Latino HealthP60MD002261 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CANINO, GLORISA J · 2007 to 2011
$8.7M
Project 1: Improving Clinical Assessment of Diagnosis for Latinos (261-295)P50MH073469 · NIMH · CAMBRIDGE HEALTH ALLIANCE · PI ALEGRIA, MARGARITA · 2005 to 2009
$4.6M
Effects of Social Context, Culture and Minority Status on Depression and AnxietyR01MH098374 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI ALEGRIA, MARGARITA, CANINO, GLORISA J · 2012 to 2016
$3.3M
An In-Depth Investigation of Racial & Ethnic Disparities in Schizophrenia CareR01MH087488 · NIMH · RAND CORPORATION · PI HORVITZ-LENNON, MARCELA V, NORMAND, SHARON-LISE TERESA · 2010 to 2012
$1.6M
NIMHD NIH HHS P60 MD0 02261NIMHD NIH HHS P60 MD002261NIMH NIH HHS P50 MH073469NIMH NIH HHS R01 MH087488NIMH NIH HHS R01MH087488PHS HHS P50 MHO 73469
6 · The paper itself

Abstract

objectiveThis study evaluated the effect of race-ethnicity and geography on the adoption of a pharmacological innovation (long-acting injectable risperidone [LAIR]) among Medicaid beneficiaries with schizophrenia as well as the contribution of geographic location to observed racial-ethnic disparities.

methodsThe data source was a claims data set from the Florida Medicaid program for the 2.5-year period that followed the launch of LAIR in the U.S. market. Study participants were beneficiaries with schizophrenia who had filled at least one antipsychotic prescription during the study period. The outcome variable was any use of LAIR; model variables were need indicators and random effects for 11 Medicaid areas, which are multicounty units used by the Medicaid program to administer benefits. Adjusted probability of use of LAIR for blacks and Latinos versus whites was estimated with logistic regression models.

resultsThe study cohort included 13,992 Medicaid beneficiaries: 25% of the cohort was black, 37% Latino, and 38% white. Unadjusted probability of LAIR use was lower for Latinos than whites, and use varied across the state's geographic areas. Adjustment for need confirmed the unadjusted finding of a disparity between Latinos and whites (odds ratio=.58, 95% confidence interval=.49-.70). The inclusion of geographic location in the model eliminated the Latino-white disparity but confirmed the unadjusted finding of geographic variation in adoption.

conclusionsWithin a state Medicaid program, the initial finding of a disparity between Latinos and whites in adopting LAIR was driven by geographic disparities in adoption rates and the geographic concentration of Latinos in a low-adoption area. Possible contributors and implications of these results are discussed.

Indexed as

Diffusion of InnovationAdultAntipsychotic AgentsCohort StudiesConfidence IntervalsEvidence-Based MedicineFemaleFloridaGeography, MedicalHealthcare DisparitiesHumansInsurance Claim ReviewMaleMedicaidMiddle AgedOdds RatioAntipsychotic AgentsRisperidone

Identifiers

PMID23026838
PMCPMC3666934
OpenAlexW2160310052

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.